Limits...
Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity.

Sharma M, Iyer JK, Shih N, Majumder M, Mattaparthi VS, Mukhopadhyay R, Doley R - PLoS ONE (2016)

Bottom Line: It exhibits strong anticoagulant and phospholipase A2 activity but is devoid of any cytotoxic effect on the tested normal or cancerous cell lines.It is found to be stable at acidic (pH 3.0) and neutral pH (pH 7.0) and has a Tm value of 71.59 ± 0.46°C.Molecular docking analysis reveals the interaction of the Ca+2 binding loop; helix C; anticoagulant region and C-terminal region of daboxin P with the heavy chain of factor Xa.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur-784028, Assam, India.

ABSTRACT
In the present study a major protein has been purified from the venom of Indian Daboia russelii russelii using gel filtration, ion exchange and Rp-HPLC techniques. The purified protein, named daboxin P accounts for ~24% of the total protein of the crude venom and has a molecular mass of 13.597 kDa. It exhibits strong anticoagulant and phospholipase A2 activity but is devoid of any cytotoxic effect on the tested normal or cancerous cell lines. Its primary structure was deduced by N-terminal sequencing and chemical cleavage using Edman degradation and tandem mass spectrometry. It is composed of 121 amino acids with 14 cysteine residues and catalytically active His48 -Asp49 pair. The secondary structure of daboxin P constitutes 42.73% of α-helix and 12.36% of β-sheet. It is found to be stable at acidic (pH 3.0) and neutral pH (pH 7.0) and has a Tm value of 71.59 ± 0.46°C. Daboxin P exhibits anticoagulant effect under in-vitro and in-vivo conditions. It does not inhibit the catalytic activity of the serine proteases but inhibits the activation of factor X to factor Xa by the tenase complexes both in the presence and absence of phospholipids. It also inhibits the tenase complexes when active site residue (His48) was alkylated suggesting its non-enzymatic mode of anticoagulant activity. Moreover, it also inhibits prothrombinase complex when pre-incubated with factor Xa prior to factor Va addition. Fluorescence emission spectroscopy and affinity chromatography suggest the probable interaction of daboxin P with factor X and factor Xa. Molecular docking analysis reveals the interaction of the Ca+2 binding loop; helix C; anticoagulant region and C-terminal region of daboxin P with the heavy chain of factor Xa. This is the first report of a phospholipase A2 enzyme from Indian viper venom which targets both factor X and factor Xa for its anticoagulant activity.

No MeSH data available.


Related in: MedlinePlus

Interaction of daboxin P with FX and FXa.(A): Fluorescence emission spectra of daboxin P, FX, and the complex (daboxin P + FX). (B) Fluorescence emission spectra of daboxin P, FXa, and the complex (daboxin P + FXa). 1 μM of daboxin P (DP) was pre-incubated with either 0.05 μM of FX or 0.1 μM of FXa for different time intervals (10 min & 20 min) at room temperature. The emission spectra of the individual proteins and the complexes were measured from 200 to 500 nm with an excitation wavelength of 280 nm using quartz cuvette (1 cm path length). (C): Electrophoretic profile of the flow through and elute obtained after affinity column chromatography. Lane 1: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 2: flow through (FX) Lane 3: FX after elution with 1.0 M NaCl, Lane 4: control (FX); Lane 5: blank; Lane 6: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 7: flow through (FXa); Lane 8: FXa after elution with 1.0 M NaCl, Lane 9: control (FXa).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4835082&req=5

pone.0153770.g011: Interaction of daboxin P with FX and FXa.(A): Fluorescence emission spectra of daboxin P, FX, and the complex (daboxin P + FX). (B) Fluorescence emission spectra of daboxin P, FXa, and the complex (daboxin P + FXa). 1 μM of daboxin P (DP) was pre-incubated with either 0.05 μM of FX or 0.1 μM of FXa for different time intervals (10 min & 20 min) at room temperature. The emission spectra of the individual proteins and the complexes were measured from 200 to 500 nm with an excitation wavelength of 280 nm using quartz cuvette (1 cm path length). (C): Electrophoretic profile of the flow through and elute obtained after affinity column chromatography. Lane 1: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 2: flow through (FX) Lane 3: FX after elution with 1.0 M NaCl, Lane 4: control (FX); Lane 5: blank; Lane 6: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 7: flow through (FXa); Lane 8: FXa after elution with 1.0 M NaCl, Lane 9: control (FXa).

Mentions: The fluorescence emission spectrum of FX and FXa was quenched by daboxin P with increasing incubation time (Fig 11A & 11B). The presence or absence of Ca+2 ions did not show any effect on the quenching spectra for both FX and FXa when treated with daboxin P (data not shown).


Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity.

Sharma M, Iyer JK, Shih N, Majumder M, Mattaparthi VS, Mukhopadhyay R, Doley R - PLoS ONE (2016)

Interaction of daboxin P with FX and FXa.(A): Fluorescence emission spectra of daboxin P, FX, and the complex (daboxin P + FX). (B) Fluorescence emission spectra of daboxin P, FXa, and the complex (daboxin P + FXa). 1 μM of daboxin P (DP) was pre-incubated with either 0.05 μM of FX or 0.1 μM of FXa for different time intervals (10 min & 20 min) at room temperature. The emission spectra of the individual proteins and the complexes were measured from 200 to 500 nm with an excitation wavelength of 280 nm using quartz cuvette (1 cm path length). (C): Electrophoretic profile of the flow through and elute obtained after affinity column chromatography. Lane 1: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 2: flow through (FX) Lane 3: FX after elution with 1.0 M NaCl, Lane 4: control (FX); Lane 5: blank; Lane 6: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 7: flow through (FXa); Lane 8: FXa after elution with 1.0 M NaCl, Lane 9: control (FXa).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4835082&req=5

pone.0153770.g011: Interaction of daboxin P with FX and FXa.(A): Fluorescence emission spectra of daboxin P, FX, and the complex (daboxin P + FX). (B) Fluorescence emission spectra of daboxin P, FXa, and the complex (daboxin P + FXa). 1 μM of daboxin P (DP) was pre-incubated with either 0.05 μM of FX or 0.1 μM of FXa for different time intervals (10 min & 20 min) at room temperature. The emission spectra of the individual proteins and the complexes were measured from 200 to 500 nm with an excitation wavelength of 280 nm using quartz cuvette (1 cm path length). (C): Electrophoretic profile of the flow through and elute obtained after affinity column chromatography. Lane 1: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 2: flow through (FX) Lane 3: FX after elution with 1.0 M NaCl, Lane 4: control (FX); Lane 5: blank; Lane 6: PageRulerTM Plus pre-stained protein ladder (250–10 kDa), Lane 7: flow through (FXa); Lane 8: FXa after elution with 1.0 M NaCl, Lane 9: control (FXa).
Mentions: The fluorescence emission spectrum of FX and FXa was quenched by daboxin P with increasing incubation time (Fig 11A & 11B). The presence or absence of Ca+2 ions did not show any effect on the quenching spectra for both FX and FXa when treated with daboxin P (data not shown).

Bottom Line: It exhibits strong anticoagulant and phospholipase A2 activity but is devoid of any cytotoxic effect on the tested normal or cancerous cell lines.It is found to be stable at acidic (pH 3.0) and neutral pH (pH 7.0) and has a Tm value of 71.59 ± 0.46°C.Molecular docking analysis reveals the interaction of the Ca+2 binding loop; helix C; anticoagulant region and C-terminal region of daboxin P with the heavy chain of factor Xa.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur-784028, Assam, India.

ABSTRACT
In the present study a major protein has been purified from the venom of Indian Daboia russelii russelii using gel filtration, ion exchange and Rp-HPLC techniques. The purified protein, named daboxin P accounts for ~24% of the total protein of the crude venom and has a molecular mass of 13.597 kDa. It exhibits strong anticoagulant and phospholipase A2 activity but is devoid of any cytotoxic effect on the tested normal or cancerous cell lines. Its primary structure was deduced by N-terminal sequencing and chemical cleavage using Edman degradation and tandem mass spectrometry. It is composed of 121 amino acids with 14 cysteine residues and catalytically active His48 -Asp49 pair. The secondary structure of daboxin P constitutes 42.73% of α-helix and 12.36% of β-sheet. It is found to be stable at acidic (pH 3.0) and neutral pH (pH 7.0) and has a Tm value of 71.59 ± 0.46°C. Daboxin P exhibits anticoagulant effect under in-vitro and in-vivo conditions. It does not inhibit the catalytic activity of the serine proteases but inhibits the activation of factor X to factor Xa by the tenase complexes both in the presence and absence of phospholipids. It also inhibits the tenase complexes when active site residue (His48) was alkylated suggesting its non-enzymatic mode of anticoagulant activity. Moreover, it also inhibits prothrombinase complex when pre-incubated with factor Xa prior to factor Va addition. Fluorescence emission spectroscopy and affinity chromatography suggest the probable interaction of daboxin P with factor X and factor Xa. Molecular docking analysis reveals the interaction of the Ca+2 binding loop; helix C; anticoagulant region and C-terminal region of daboxin P with the heavy chain of factor Xa. This is the first report of a phospholipase A2 enzyme from Indian viper venom which targets both factor X and factor Xa for its anticoagulant activity.

No MeSH data available.


Related in: MedlinePlus